TK-112690

TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis[1][2][3].

22423-26-3

12352005

H302, H315, H319, H335

Others

Others

COVID-19-immunoregulation

Cancer; Inflammation/Immunology

10mM

99.91

DMSO : 50 mg/mL (ultrasonic)

CC(C1=O)=CN(C2=N1)[C@@]3([H])[C@](O2)([H])[C@@](O)([H])[C@@](O3)([H])CO

C10H12N2O5

240.21

H302, H315, H319, H335

[1]Strefeler A, et al. Nucleosides are overlooked fuels in central carbon metabolism. Trends Endocrinol Metab. 2024 Apr;35 (4) :290-299. |[2]William A. Garland, et al. Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same. US 9,382,287 B2. United States Patent and Trademark Office (USPTO) . Jul. 5, 2016. |[3]William A. Garland, et al. Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease. US 2025/0222000 A1. United States Patent and Trademark Office (USPTO) . Jul. 10, 2025.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

http://file.medchemexpress.com/batch_PDF/HY-W008491/TK-112690-SDS-MedChemExpress.pdf

Reference compound2

No Development Reported